Our Commitment to Pharmaceutical Excellence
Pioneering healthcare solutions since 2005 with a focus on innovation, quality, and accessibility
Pioneering healthcare solutions since 2005 with a focus on innovation, quality, and accessibility
Our global impact in pharmaceutical innovation
Years of Excellence
Countries Served
Dedicated Employees
GMP Facilities
Two decades of transforming healthcare
Founded in 2005 by Dr. Dean Rodriguez, Deano Biotic began as a 12-person research lab in Mumbai focused on cardiovascular medications. Our first breakthrough came in 2008 with CardioPlus, which reduced hypertension treatment costs by 60% while maintaining efficacy.
By 2010, we had served over 500,000 patients across India and established our first GMP-certified manufacturing facility.
We launched operations in 8 new countries across Southeast Asia and Africa, building our first overseas GMP facility in Singapore in 2014. During this period, we introduced 14 new products targeting tropical diseases, with our malaria treatment reaching 1.2 million patients by 2015.
Our international team grew to 450 employees across three continents during this expansion phase.
Today, with 1,500 employees across 8 GMP facilities, we're pioneering mRNA vaccine technology and AI-driven drug discovery. Our current pipeline includes 8 gene therapies in clinical trials and a $50M investment in quantum computing applications for molecular modeling.
We maintain a 4.8/5 employee satisfaction rating through our "Science With Compassion" program that connects researchers with patient stories.
Moments that defined our journey
Established with 12 employees and one research facility focused on cardiovascular medications.
Launched operations in Southeast Asia and Africa, introducing our products to 8 new countries.
Received International Pharmaceutical Excellence Prize for antimicrobial resistance work.
Pioneering the future of healthcare innovation
We're launching 8 gene therapies by 2025, with our first product entering Phase 3 trials this year. Our $75M genomic research center in Bangalore will accelerate personalized medicine development.
These therapies target rare genetic disorders affecting over 2 million patients worldwide, with treatments projected to be 40% more affordable than current options.
Our $50M AI initiative has reduced drug discovery timelines by 40%. The 2024 Quantum Computing Division will accelerate molecular simulations by 10,000x, revolutionizing our R&D capabilities.
We're training 200 scientists in AI applications and expect to file 15 new drug patents annually by 2026 using these technologies.
Three facilities now operate on 100% renewable energy. Our 2030 roadmap includes carbon-neutral operations and 100% biodegradable packaging across all products.
We've achieved a 78% reduction in hazardous waste since 2018 while increasing production yields by 22% through green chemistry innovations.